Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Eli Lilly (LLY) ended the recent trading session at $762.18, demonstrating a -1.23% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14% ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock.

Fool.com contributor Parkev Tatevosian discusses the prospects for Eli Lilly stock. *Stock prices used were the afternoon prices of June 14, 2024. The video was published on June 16, 2024.

Our investment thesis delves into the potential of Eli Lilly's (NYSE:LLY) Mounjaro, a diabetes drug that has shown promising results in off-label use for weight loss.We explore the drug's impact ...

Eli Lilly and Company (NYSE:LLY), a global pharmaceutical giant with a market capitalization of $700 billion, has been at the forefront of innovation in the biopharmaceutical industry ...

I recommend buying Eli Lilly and Company stock after strong Q2 ... (Technical Analysis) Aug. 12, 2024 9:37 AM ET Eli Lilly and ... We are not investment advisers and we never recommend stocks or ...

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at $875.00. Mohit Bansal has given his Buy rating due to a ...

Eli Lilly set some ambitious goals for 2023, highlighting a promising mix of assets in its portfolio. The company has obtained multiple drug approvals this year. It has also upgraded its guidance.

Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.